Versiti, a national leader in blood health innovation, today announced the acquisition of Missouri-based Ethical and Independent Review Services (E&I). Further expanding Versiti’s clinical trial services and expertise, E&I provides independent institutional review board (IRB) services to ensure thorough, timely reviews of research involving human subjects.
“Versiti and E&I share a mission-focused approach to advancing medical science and patient care through clinical trials,” said Versiti President and CEO Chris Miskel. “Joining forces with E&I allows us to expand our services to additional research areas with an industry-leading, best practice approach.”
An AAHRPP-accredited independent IRB, E&I provides in-depth regulatory expertise to support the development of ethical and quality research designs for social and behavioral research as well as the biopharmaceutical and medical device industries.